Sign up for Table of Contents Alerts.

Email this page

Print this page

News

Morphotek CEO Named Ernst & Young Entrepreneur Of The Year

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Nicholas C. Nicolaides, Ph.D., president and chief executive officer of Morphotek, Inc., a U.S. subsidiary of Eisai Co., Ltd., was awarded the Ernst & Young Entrepreneur Of The Year; for his innovations and contributions to the life science industry in the Greater Philadelphia Region. Dr. Nicolaides was honored for his development of a whole genome evolution technology called morphogenics, which became the basis for Morphotek, a biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies.

The Greater Philadelphia Regional Entrepreneur of the Year Award Ceremony, held at the Lowes Hotel in Philadelphia last Thursday, celebrated local entrepreneurs and the pioneering businesses they have developed. The Ernst & Young Entrepreneur Of The Year award, in its 21st year, seeks to recognize outstanding entrepreneurs who are building and leading dynamic, growing businesses. Awards are given to entrepreneurs who have demonstrated excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.

"I am deeply honored to be recognized as a pioneer and innovator in the life sciences industry; but my entrepreneurial success is attributed to Morphotek's tremendous talent pool, exception executive management team and our shared desire to develop effective treatments that will change the fate of terminally ill patients, said Nicolaides. "This award not only acknowledges the ability to create a business and implement it effectively, but it acknowledges a superior level of social responsibility: Morphotek's ability to leverage talent and resources to positively impact the Greater Philadelphia region," added Nicolaides.

As a regional award winner, Dr. Nicolaides is now eligible for consideration for the Ernst & Young Entrepreneur Of The Year 2007 national program. Award winners will be announced at the annual awards gala in Palm Springs, California on November 17, 2007.

About Morphotek

Morphotek, Inc., a U.S. subsidiary of Eisai Co., Ltd., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three areas of therapeutic focus: Integrative neuroscience including neurology and psychiatric medicines; gastrointestinal disorders; and integrative oncology including oncotherapy and supportive-care treatments. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 9,000 people worldwide. More than 50 percent of the group sales are derived from overseas business. For more information, please visit www.eisai.co.jp.

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.